PL3788040T3 - Pirydazynony jako inhibitory parp7 - Google Patents
Pirydazynony jako inhibitory parp7Info
- Publication number
- PL3788040T3 PL3788040T3 PL19723272.1T PL19723272T PL3788040T3 PL 3788040 T3 PL3788040 T3 PL 3788040T3 PL 19723272 T PL19723272 T PL 19723272T PL 3788040 T3 PL3788040 T3 PL 3788040T3
- Authority
- PL
- Poland
- Prior art keywords
- pyridazinones
- parp7
- inhibitors
- parp7 inhibitors
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862664544P | 2018-04-30 | 2018-04-30 | |
PCT/US2019/029582 WO2019212937A1 (en) | 2018-04-30 | 2019-04-29 | Pyridazinones as parp7 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3788040T3 true PL3788040T3 (pl) | 2023-08-07 |
Family
ID=66476851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL19723272.1T PL3788040T3 (pl) | 2018-04-30 | 2019-04-29 | Pirydazynony jako inhibitory parp7 |
Country Status (34)
Country | Link |
---|---|
US (5) | US10550105B2 (pl) |
EP (2) | EP3788040B1 (pl) |
JP (2) | JP6942896B2 (pl) |
KR (1) | KR20210014108A (pl) |
CN (1) | CN112424188A (pl) |
AR (1) | AR121419A1 (pl) |
AU (2) | AU2019262927B2 (pl) |
BR (1) | BR112020022006A2 (pl) |
CA (1) | CA3098585A1 (pl) |
CL (1) | CL2020002821A1 (pl) |
CO (1) | CO2020013599A2 (pl) |
CR (1) | CR20200518A (pl) |
CY (1) | CY1126132T1 (pl) |
DK (1) | DK3788040T3 (pl) |
EA (1) | EA202092590A1 (pl) |
EC (1) | ECSP20069404A (pl) |
ES (1) | ES2949538T3 (pl) |
FI (1) | FI3788040T3 (pl) |
HR (1) | HRP20230458T1 (pl) |
HU (1) | HUE062096T2 (pl) |
IL (2) | IL278116B2 (pl) |
LT (1) | LT3788040T (pl) |
MA (1) | MA52486B1 (pl) |
MD (1) | MD3788040T2 (pl) |
MX (2) | MX2020011465A (pl) |
PE (1) | PE20211382A1 (pl) |
PH (1) | PH12020551760A1 (pl) |
PL (1) | PL3788040T3 (pl) |
PT (1) | PT3788040T (pl) |
RS (1) | RS64283B1 (pl) |
SG (1) | SG11202010183XA (pl) |
SI (1) | SI3788040T1 (pl) |
TW (2) | TW202344505A (pl) |
WO (1) | WO2019212937A1 (pl) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019212946A1 (en) | 2018-04-30 | 2019-11-07 | Ribon Therapeutics Inc. | Screening methods for parp modulators |
IL278116B2 (en) * | 2018-04-30 | 2024-04-01 | Ribon Therapeutics Inc | Pyridazines as PAR7 inhibitors |
US11512090B2 (en) | 2018-06-11 | 2022-11-29 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
EP3846806A4 (en) | 2018-09-04 | 2022-06-08 | Pipeline Therapeutics, Inc. | MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS |
US20220162196A1 (en) * | 2019-04-29 | 2022-05-26 | Ribon Therapeutics, Inc. | Solid forms of a parp7 inhibitor |
AU2020363381A1 (en) * | 2019-10-07 | 2022-04-07 | Contineum Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
WO2021087018A1 (en) * | 2019-10-30 | 2021-05-06 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
KR20220109401A (ko) | 2019-10-30 | 2022-08-04 | 리본 테라퓨틱스 인코포레이티드 | Parp7 억제제로서의 피리다진온 |
US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
EP4161923A4 (en) * | 2020-06-09 | 2023-10-11 | Relive Therapeutics Inc. | COMPOUNDS WITH A THREE RING CORE AS PD-1/PD-L1 BLOCKERS |
CN113880843B (zh) * | 2020-07-03 | 2023-03-10 | 武汉朗来科技发展有限公司 | 一种杂环化合物及其应用 |
WO2022111700A1 (zh) * | 2020-11-27 | 2022-06-02 | 成都百裕制药股份有限公司 | 哒嗪酮衍生物及其在医药上的应用 |
WO2022156708A1 (en) * | 2021-01-20 | 2022-07-28 | Jacobio Pharmaceuticals Co., Ltd. | Parp7 enzyme inhibitor |
CN116724044A (zh) * | 2021-02-03 | 2023-09-08 | 上海湃隆生物科技有限公司 | 三并杂环类化合物、其制备方法及其应用 |
EP4289846A1 (en) * | 2021-02-07 | 2023-12-13 | Wuhan LL Science and Technology Development Co., Ltd. | Heterocyclic compound, and intermediate thereof, preparation method therefor and use thereof |
CA3210885A1 (en) * | 2021-02-09 | 2022-08-18 | Jacobio Pharmaceuticals Co., Ltd. | Tricyclic derivatives useful as parp7 inhibitors |
US20220265654A1 (en) * | 2021-02-16 | 2022-08-25 | Ribon Therapeutics, Inc. | Dosage regimens for parp7 inhibitors |
CN115028648B (zh) * | 2021-03-03 | 2024-08-30 | 武汉誉祥医药科技有限公司 | 三并环化合物及其药物组合物和应用 |
CN117425648A (zh) * | 2021-03-12 | 2024-01-19 | 杭州英创医药科技有限公司 | 作为parp7抑制剂的化合物 |
MX2023011378A (es) | 2021-03-31 | 2023-10-06 | Duke Street Bio Ltd | Compuesto farmaceutico. |
CN117083274A (zh) * | 2021-04-23 | 2023-11-17 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
EP4342896A1 (en) * | 2021-05-21 | 2024-03-27 | Chengdu Baiyu Pharmaceutical Co., Ltd. | Piperazine derivative and use thereof in medicine |
CN117396485A (zh) * | 2021-05-25 | 2024-01-12 | 轩竹生物科技股份有限公司 | Parp7抑制剂 |
CN115477640A (zh) * | 2021-05-31 | 2022-12-16 | 由理生物医药(上海)有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
WO2023001247A1 (zh) * | 2021-07-21 | 2023-01-26 | 南京明德新药研发有限公司 | 哒嗪酮类化合物 |
WO2023001296A1 (zh) * | 2021-07-23 | 2023-01-26 | 武汉人福创新药物研发中心有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
WO2023011629A1 (zh) * | 2021-08-06 | 2023-02-09 | 成都百裕制药股份有限公司 | 吡咯烷酮衍生物及其在医药上的应用 |
CN117377665A (zh) * | 2021-08-16 | 2024-01-09 | 北京华森英诺生物科技有限公司 | Parp7抑制剂及其应用 |
JP2024532845A (ja) * | 2021-08-17 | 2024-09-10 | インベンティスバイオ カンパニー リミテッド | ピリダジノンまたはピリジノン化合物、その製造方法および用途 |
KR20240091056A (ko) | 2021-10-28 | 2024-06-21 | 길리애드 사이언시즈, 인코포레이티드 | 피리디진-3(2h)-온 유도체 |
CN115745971B (zh) * | 2021-12-20 | 2024-07-30 | 北京华森英诺生物科技有限公司 | Parp7抑制剂及其应用 |
CN116375688A (zh) * | 2021-12-23 | 2023-07-04 | 中国药科大学 | 哒嗪酮类化合物及其制备方法、药物组合物和应用 |
WO2023143236A1 (zh) * | 2022-01-26 | 2023-08-03 | 中国药科大学 | 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用 |
CN116535395B (zh) * | 2022-01-26 | 2024-07-09 | 中国药科大学 | 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用 |
KR20240021923A (ko) * | 2022-04-01 | 2024-02-19 | 노보스타 파마슈티컬스, 리미티드 | Parp7 억제제 및 이의 용도 |
TW202346294A (zh) * | 2022-04-21 | 2023-12-01 | 大陸商四川海思科製藥有限公司 | 吡嗪酮衍生物及其在醫藥上的應用 |
WO2024032410A1 (zh) * | 2022-08-09 | 2024-02-15 | 成都百裕制药股份有限公司 | 哌嗪类化合物和pd-1抑制剂或pd-l1抑制剂的组合物以及其治疗肿瘤的用途 |
WO2024032409A1 (zh) * | 2022-08-09 | 2024-02-15 | 成都百裕制药股份有限公司 | 哌嗪类化合物在联合放疗治疗肿瘤中的用途 |
WO2024037558A1 (en) * | 2022-08-17 | 2024-02-22 | Jacobio Pharmaceuticals Co., Ltd. | Solid forms of compound i or salts thereof |
GB202213819D0 (en) | 2022-09-22 | 2022-11-09 | Duke Street Bio Ltd | Pharmaceutical compound |
CN115490671B (zh) * | 2022-10-21 | 2024-05-14 | 水木未来(北京)科技有限公司 | Parp7抑制剂及其制备方法 |
CN118027039A (zh) * | 2022-11-14 | 2024-05-14 | 成都百裕制药股份有限公司 | 一种取代的哌嗪衍生物的晶体及其制备方法 |
GB202217888D0 (en) | 2022-11-29 | 2023-01-11 | Duke Street Bio Ltd | Pharmaceutical compound |
WO2024146631A1 (zh) * | 2023-01-06 | 2024-07-11 | 齐鲁制药有限公司 | 一种parp7抑制剂的制备方法 |
WO2024149231A1 (en) * | 2023-01-10 | 2024-07-18 | Angel Pharmaceutical Co., Ltd. | Parp7 inhibitors and uses thereof |
WO2024149234A1 (en) * | 2023-01-10 | 2024-07-18 | Angel Pharmaceutical Co., Ltd. | Parp7 inhibitors and uses thereof |
CN118388414A (zh) * | 2023-01-17 | 2024-07-26 | 中国药科大学 | 哒嗪酮类化合物及其制备方法、药物组合物和应用 |
CN117342983B (zh) * | 2023-12-05 | 2024-02-06 | 康羽生命科学技术(苏州)有限公司 | 过乙酰化GalNAc-L96合成方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0957365B1 (en) | 1997-09-05 | 2006-02-01 | Matsushita Electric Industrial Co., Ltd. | Fluorescence polarization method |
WO2002082082A2 (en) | 2001-04-09 | 2002-10-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorescence polarization assay |
HU227237B1 (en) * | 2001-09-27 | 2010-12-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them |
GB0301628D0 (en) | 2002-09-19 | 2003-02-26 | Aventis Pharma Inc | Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP) |
NZ551680A (en) * | 2004-06-30 | 2010-02-26 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as PARP inhibitors |
GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
EP2492263A1 (en) | 2006-07-25 | 2012-08-29 | Cephalon, Inc. | Pyridizinone Derivatives |
JP5758630B2 (ja) * | 2007-11-15 | 2015-08-05 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Parp阻害剤としてのピリダジノン誘導体 |
RU2490260C2 (ru) * | 2008-03-27 | 2013-08-20 | Янссен Фармацевтика Нв | Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина |
EP3205647B1 (en) * | 2009-08-17 | 2020-05-13 | Memorial Sloan-Kettering Cancer Center | 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders |
CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
JP2016512239A (ja) * | 2013-03-15 | 2016-04-25 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物 |
WO2016116602A1 (en) * | 2015-01-23 | 2016-07-28 | Astrazeneca Ab | Treatment of cancer |
CN106749261A (zh) * | 2015-11-23 | 2017-05-31 | 中国科学院上海药物研究所 | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 |
TWI785022B (zh) | 2017-03-28 | 2022-12-01 | 美商富曼西公司 | 新穎噠嗪酮類除草劑 |
US20230203028A1 (en) * | 2017-09-18 | 2023-06-29 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
GB201717080D0 (en) | 2017-10-18 | 2017-11-29 | Syngenta Participations Ag | Chemical process |
IL278116B2 (en) | 2018-04-30 | 2024-04-01 | Ribon Therapeutics Inc | Pyridazines as PAR7 inhibitors |
WO2019212946A1 (en) | 2018-04-30 | 2019-11-07 | Ribon Therapeutics Inc. | Screening methods for parp modulators |
US20220162196A1 (en) | 2019-04-29 | 2022-05-26 | Ribon Therapeutics, Inc. | Solid forms of a parp7 inhibitor |
KR20220109401A (ko) | 2019-10-30 | 2022-08-04 | 리본 테라퓨틱스 인코포레이티드 | Parp7 억제제로서의 피리다진온 |
WO2021087018A1 (en) | 2019-10-30 | 2021-05-06 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
-
2019
- 2019-04-29 IL IL278116A patent/IL278116B2/en unknown
- 2019-04-29 ES ES19723272T patent/ES2949538T3/es active Active
- 2019-04-29 DK DK19723272.1T patent/DK3788040T3/da active
- 2019-04-29 EA EA202092590A patent/EA202092590A1/ru unknown
- 2019-04-29 HR HRP20230458TT patent/HRP20230458T1/hr unknown
- 2019-04-29 PL PL19723272.1T patent/PL3788040T3/pl unknown
- 2019-04-29 TW TW112127538A patent/TW202344505A/zh unknown
- 2019-04-29 PT PT197232721T patent/PT3788040T/pt unknown
- 2019-04-29 MD MDE20210210T patent/MD3788040T2/ro unknown
- 2019-04-29 AR ARP190101124A patent/AR121419A1/es unknown
- 2019-04-29 LT LTEPPCT/US2019/029582T patent/LT3788040T/lt unknown
- 2019-04-29 CR CR20200518A patent/CR20200518A/es unknown
- 2019-04-29 BR BR112020022006-0A patent/BR112020022006A2/pt unknown
- 2019-04-29 CN CN201980044076.5A patent/CN112424188A/zh active Pending
- 2019-04-29 EP EP19723272.1A patent/EP3788040B1/en active Active
- 2019-04-29 RS RS20230450A patent/RS64283B1/sr unknown
- 2019-04-29 FI FIEP19723272.1T patent/FI3788040T3/fi active
- 2019-04-29 MX MX2020011465A patent/MX2020011465A/es unknown
- 2019-04-29 CA CA3098585A patent/CA3098585A1/en active Pending
- 2019-04-29 IL IL308983A patent/IL308983A/en unknown
- 2019-04-29 HU HUE19723272A patent/HUE062096T2/hu unknown
- 2019-04-29 SG SG11202010183XA patent/SG11202010183XA/en unknown
- 2019-04-29 PE PE2020001749A patent/PE20211382A1/es unknown
- 2019-04-29 SI SI201930544T patent/SI3788040T1/sl unknown
- 2019-04-29 MA MA52486A patent/MA52486B1/fr unknown
- 2019-04-29 US US16/397,103 patent/US10550105B2/en active Active
- 2019-04-29 JP JP2020560916A patent/JP6942896B2/ja active Active
- 2019-04-29 KR KR1020207034323A patent/KR20210014108A/ko not_active Application Discontinuation
- 2019-04-29 WO PCT/US2019/029582 patent/WO2019212937A1/en unknown
- 2019-04-29 AU AU2019262927A patent/AU2019262927B2/en active Active
- 2019-04-29 TW TW108114978A patent/TWI811353B/zh active
- 2019-04-29 EP EP23161423.1A patent/EP4234551A3/en active Pending
- 2019-10-24 US US16/662,409 patent/US10870641B2/en active Active
-
2020
- 2020-08-11 US US16/990,677 patent/US11014913B2/en active Active
- 2020-10-22 PH PH12020551760A patent/PH12020551760A1/en unknown
- 2020-10-29 CO CONC2020/0013599A patent/CO2020013599A2/es unknown
- 2020-10-29 MX MX2023005804A patent/MX2023005804A/es unknown
- 2020-10-29 EC ECSENADI202069404A patent/ECSP20069404A/es unknown
- 2020-10-29 CL CL2020002821A patent/CL2020002821A1/es unknown
-
2021
- 2021-04-12 US US17/227,705 patent/US11566020B1/en active Active
- 2021-09-08 JP JP2021145986A patent/JP7518049B2/ja active Active
-
2022
- 2022-10-27 US US17/974,830 patent/US20230192664A1/en not_active Abandoned
-
2023
- 2023-07-03 CY CY20231100310T patent/CY1126132T1/el unknown
-
2024
- 2024-01-30 AU AU2024200566A patent/AU2024200566A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL278116A (en) | Pyridazines as PAR7 inhibitors | |
IL283639A (en) | kif18a inhibitors | |
IL269196A (en) | New inhibitors | |
IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
EP3706747A4 (en) | PRMT5 INHIBITORS | |
IL274207A (en) | Aminoimidazopyridazines as kinase inhibitors | |
ZA201907136B (en) | Ip6k inhibitors | |
EP3706742A4 (en) | PRMT5 INHIBITORS | |
IL276013A (en) | pi4kiiibeta inhibitors | |
EP3600301A4 (en) | KDM4 INHIBITORS | |
IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | |
IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
GB201807845D0 (en) | Kinase Inhibitors | |
GB201812462D0 (en) | Inhibitors | |
GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
GB201905476D0 (en) | MAPA4K4 Inhibitors | |
GB201809939D0 (en) | Eastase inhibitor | |
GB201721465D0 (en) | Inhibitors | |
GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors |